Avantor (AVTR) 주식 개요
는 미주, 유럽, 아시아, 중동 및 아프리카의 바이오 제약, 의료, 교육 및 정부, 첨단 기술 및 응용 재료 산업 분야의 고객에게 미션 크리티컬 제품 및 서비스를 제공하는 회사입니다. 자세히 보기
AVTR Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Avantor, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$8.14 |
| 52주 최고가 | US$15.93 |
| 52주 최저가 | US$7.27 |
| 베타 | 0.93 |
| 1개월 변동 | 3.04% |
| 3개월 변동 | -10.15% |
| 1년 변동 | -38.10% |
| 3년 변동 | -60.45% |
| 5년 변동 | -74.04% |
| IPO 이후 변동 | -43.86% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking AlphaRecent updates
내러티브 업데이트 • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 16
AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing
Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.내러티브 업데이트 • Apr 02
AVTR: Reset Expectations And Share Repurchases May Support Future Upside
The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.내러티브 업데이트 • Mar 19
AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing
Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.내러티브 업데이트 • Mar 05
AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential
Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.분석 기사 • Feb 13
The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...내러티브 업데이트 • Feb 04
AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations
Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.내러티브 업데이트 • Jan 21
AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility
Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.내러티브 업데이트 • Jan 07
AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential
Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.내러티브 업데이트 • Dec 14
AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves
Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.내러티브 업데이트 • Nov 28
AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead
Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.내러티브 업데이트 • Nov 14
AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025
Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.분석 기사 • Nov 01
Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...내러티브 업데이트 • Oct 31
AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery
Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.분석 기사 • Oct 28
There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise
Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...내러티브 업데이트 • Oct 16
Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.분석 기사 • Sep 12
We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Aug 12
Concerns Surrounding Avantor's (NYSE:AVTR) Performance
NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...분석 기사 • Jun 26
What Is Avantor, Inc.'s (NYSE:AVTR) Share Price Doing?
Avantor, Inc. ( NYSE:AVTR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Seeking Alpha • Apr 26
Avantor: A Healthier Diagnosis As Expectations Cool
Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Avantor: Mundane Business, Solid Cash Flow, Potential New Risks
Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold? An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Avantor: Durable FCF Generator Trading For Cheap
Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking AlphaSeeking Alpha • Oct 24
Avantor: Uninspiring, Even Amidst Some Green Shoots
Summary Avantor shares have struggled on the back of a high valuation, significant debt, and lackluster growth, despite recent improvements in organic sales and a divestment. The company operates two segments: a $4.7 billion laboratory solutions business, and a $2.2 billion bioscience production business, with the latter having higher margins. Recent financials show declining sales and earnings, amidst high valuation and a demanding valuation. A $650 million divestment aims to reduce debt, but the overall risk-reward remains unattractive given the company's past performance and high leverage. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 21
New Operating Model And Bioprocessing Innovations Promise Robust Growth And Market Leadership
Implementation of a new operating model and ongoing cost transformation initiatives are streamlining execution and improving net margins through cost savings.Seeking Alpha • Aug 13
Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold
Summary AVTR stock is up 18% post Q2 FY'24 earnings, but momentum and quality continue to diverge. The company's balance sheet is saddled with debt, whilst earnings produced on capital are flattening. Valuations are unsupportive at >35x earnings, and I continue to rate AVTR a hold with little headroom for upside under present conditions. Read the full article on Seeking Alpha주주 수익률
| AVTR | US Life Sciences | US 시장 | |
|---|---|---|---|
| 7D | 6.5% | 2.0% | 2.5% |
| 1Y | -38.1% | 5.3% | 26.4% |
수익률 대 산업: AVTR은 지난 1년 동안 5.3%의 수익을 기록한 US Life Sciences 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: AVTR은 지난 1년 동안 26.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| AVTR volatility | |
|---|---|
| AVTR Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: AVTR는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: AVTR의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1904 | 13,500 | Emmanuel Ligner | www.avantorsciences.com |
는 미주, 유럽, 아시아, 중동 및 아프리카의 바이오 제약, 의료, 교육 및 정부, 첨단 기술 및 응용 재료 산업 분야의 고객에게 미션 크리티컬 제품 및 서비스를 제공하는 기업입니다. 이 회사는 순도 화학물질 및 시약, 실험실 제품 및 소모품, 배합 실리콘 재료, 맞춤형 부형제, 맞춤형 일회용 어셈블리, 공정 크로마토그래피 수지 및 컬럼, 분석 샘플 준비 키트, 교육 및 미생물학 제품, 임상시험 키트, 유체 취급 팁 등의 재료 및 소모품을 제공합니다. 또한 여과 시스템, 바이러스 비활성화 시스템, 인큐베이터, 분석 기기, 증발기, 초저온 냉동고, 생물학적 안전 캐비닛, 연동 펌프, 중요 환경 용품 등의 장비 및 계측 제품도 제공합니다.
Avantor, Inc. 기초 지표 요약
| AVTR 기초 통계 | |
|---|---|
| 시가총액 | US$5.54b |
| 순이익 (TTM) | -US$551.40m |
| 매출 (TTM) | US$6.55b |
0.8x
주가매출비율(P/S)-10.1x
주가수익비율(P/E)AVTR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| AVTR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$6.55b |
| 매출원가 | US$4.45b |
| 총이익 | US$2.11b |
| 기타 비용 | US$2.66b |
| 순이익 | -US$551.40m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.81 |
| 총이익률 | 32.13% |
| 순이익률 | -8.42% |
| 부채/자본 비율 | 67.8% |
AVTR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 17:23 |
| 종가 | 2026/05/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Avantor, Inc.는 29명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |